Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More
Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More
Preliminary cSCI and stroke Phase I data presented at Phacilitate Cell & Gene Therapy World conference, with collective trial data analysis showing NSI-566 consistently demonstrated biological activity of motor improvement in all three ongoing cell therapy trial indications. More
Researchers concluded Neuralstem’s novel neuroprotective cortical cells engineered to express insulin-like growth factor-1 should be further studied as a possible disease-modifying Alzheimer’s intervention, in Stem Cells Translational Medicine. More
Report cites Neuralstem’s first-in-class lead oral, small molecule safe and well-tolerated in major depressive disorder, with medium to large clinical effect size for all measures, with positive effects persisting after patients stopped receiving the drug. More
Business update includes NSI-189/MDD Phase II protocol filed with the FDA and patient enrollment expected 1Q2016, and NSI-566/cSCI positive Phase I safety data presented in Oct. More
Nine-month Phase II and combined Phase I/II NSI-566 ALS data was safe and well-tolerated; no acceleration of disease progression, and forced vital capacity (FVC) preservation correlated most strongly with ALSFRSr scores. More
Neuralstem, Inc. announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.'s patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015. More
Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015 under the symbol "CUR." More
Neuralstem's HK532-IGF-1 cells enhanced learning cognition and memory consolidation in animal data presented by University of Michigan researchers, who also reported beta-amyloid plaque reduction in the cortex and hippocampus. More
Former CFO and/or VP of three biotech/ pharma companies and former Senior Director, Corporate Development, for Genzyme brings expertise in corporate finance, licensing, and partnering. More
Cervical intervention deemed safe, 16 million cells maximum tolerated dose established, and secondary efficacy endpoints reviewed. More
Depression blood-based biomarker analysis presented at CNS Summit shows NSI-189 rapidly and persistently efficacious. More